Correlation Between Viatris and Esperion Therapeutics
Can any of the company-specific risk be diversified away by investing in both Viatris and Esperion Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Viatris and Esperion Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Viatris and Esperion Therapeutics, you can compare the effects of market volatilities on Viatris and Esperion Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Viatris with a short position of Esperion Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Viatris and Esperion Therapeutics.
Diversification Opportunities for Viatris and Esperion Therapeutics
0.74 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Viatris and Esperion is 0.74. Overlapping area represents the amount of risk that can be diversified away by holding Viatris and Esperion Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Esperion Therapeutics and Viatris is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Viatris are associated (or correlated) with Esperion Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Esperion Therapeutics has no effect on the direction of Viatris i.e., Viatris and Esperion Therapeutics go up and down completely randomly.
Pair Corralation between Viatris and Esperion Therapeutics
Given the investment horizon of 90 days Viatris is expected to generate 2.69 times less return on investment than Esperion Therapeutics. But when comparing it to its historical volatility, Viatris is 3.08 times less risky than Esperion Therapeutics. It trades about 0.06 of its potential returns per unit of risk. Esperion Therapeutics is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest 142.00 in Esperion Therapeutics on August 31, 2024 and sell it today you would earn a total of 112.00 from holding Esperion Therapeutics or generate 78.87% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Significant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Viatris vs. Esperion Therapeutics
Performance |
| Timeline |
| Viatris |
| Esperion Therapeutics |
Viatris and Esperion Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Viatris and Esperion Therapeutics
The main advantage of trading using opposite Viatris and Esperion Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Viatris position performs unexpectedly, Esperion Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Esperion Therapeutics will offset losses from the drop in Esperion Therapeutics' long position.The idea behind Viatris and Esperion Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.| Esperion Therapeutics vs. Bausch Health Companies | Esperion Therapeutics vs. Haleon plc | Esperion Therapeutics vs. Intracellular Th |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Complementary Tools
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| CEOs Directory Screen CEOs from public companies around the world |